Back to Authors

Jørgensen, Judit

0000-0001-9784-2703

A5110919388 | I2802335433

Mayo Clinic

Aarhus University Hospital

Citations 13

SAFETY AND EFFICACY OF THE PD‐L1 INHIBITOR DURVALUMAB WITH R‐CHOP OR R2‐CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH‐RISK DLBCL

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 132-134

10.1002/hon.93_2629

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 231-232

10.1002/hon.44_2630

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study

Blood Advances | July 5, 2018 | Volume: 2 | Issue: 13 | Pages: 1562-1571

10.1182/bloodadvances.2018017673 | PMID 29976619

Key PointsPatients who received R-chemo followed by MR had an improved 5-year PFS and OS independent of prognostic factors. A reduction of the risk of HT was observed among the MR patients of the training, but not of the validation, cohort.